MiR-148a-3p demonstrates strong efficacy in distinguishing metastatic from non-metastatic HCC patients (AUC = 0.800, sensitivity 88.89%, specificity 60.0%), with its downregulation correlating with elevated TGF-β1, distant metastasis, multinodular disease, and advanced TNM stages, highlighting its potential as a diagnostic biomarker for HCC metastasis [149]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.